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Abstract
New chemical entities are desperately needed that overcome the limitations of existing drugs for neglected diseases.
Screening a diverse library of 10,000 drug-like compounds against 7 neglected disease pathogens resulted in an integrated
dataset of 744 hits. We discuss the prioritization of these hits for each pathogen and the strong correlation observed
between compounds active against more than two pathogens and mammalian cell toxicity. Our work suggests that the
efficiency of early drug discovery for neglected diseases can be enhanced through a collaborative, multi-pathogen
approach.
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Introduction
The search for new antiparasitic drugs for use in humans has
accelerated in the past decade, based partly on the growing
recognition that addressing these widespread infections is neces-
sary for poverty reduction. There is a consensus that the drugs
available for these pathogens are far from optimal, plagued by
susceptibility to resistance, lack of activity against key species (or
stages of the life cycle), lack of adequate efficacy in field-
compatible delivery regimens, and reliant on single agents for
control programmes [1,2]. Expansion of programs for discovery
and development of new compounds has been fueled by
investment from donor organizations (such as the Bill and Melinda
Gates Foundation and the Wellcome Trust) and increasing
participation of the pharmaceutical industry. Some companies
have established drug discovery centers for a select set of diseases.
For example, the Novartis Institute in Singapore is focusing on
malaria, dengue and tuberculosis and the GlaxoSmithKline (GSK)
facility in Tres Cantos, Spain, is expanding its efforts to include a
number of neglected diseases. We have also witnessed drug
donation programmes essential for filariasis control by Merck and
GSK as well as praziquantel donation by Merck Serono. This
effort has been extended to sharing of proprietary and non-
proprietary screening data, exemplified by the recent publication
of screening results of corporate compound libraries against
malaria parasites [3,4]. In another development, Novo Nordisk
transferred its entire compound library to the National Centre for
Drug Screening in Shanghai to support drug discovery for
neglected tropical diseases (NTDs) and related capacity building,
in collaboration with The Special Programme for Research and
Training in Tropical Diseases, at the World Health Organization
(WHO/TDR) [5].
WHO-TDR has a long history of drug discovery and
development for NTDs [1,6,7]. For several decades (1970–2000),
it was the primary source of support for systematic antiparasitic
screening programmes outside of military institutions and animal
health companies [8,9]. Since then, the creation and evolution of
Product Development Partnership (PDP) organizations such as the
Medicines for Malaria Venture (MMV), Drugs for Neglected
Diseases initiative (DNDi) and Institute for One World Health
(iOWH) to support development of promising drugs has become
an important factor in bringing modern approaches to pharma-
ceutical research on neglected diseases [1,10]. The development of
sophisticated antiparasitic drug discovery activities in countries
such as India, Brazil, South Africa and China, and increasingly in
less developed countries in which these diseases are endemic,
introduces new and influential contributors to the renaissance in
this area [11]. Furthermore, the continuing efforts of the animal
health industry in antiparasitic discovery, particularly in the area
of anthelmintics, are being incorporated into human discovery
programs [12]; almost all available human anthelmintics were
initially developed for use in veterinary settings.
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chemical entities for neglected diseases remain, and apart from
some repurposed drugs and few new molecules for malaria
[13,14,15], the international community has not been able to
transition novel chemical entities from discovery into development
in the past 15 years. An innovation gap has therefore been defined
for the various phases of the drug discovery process [16]. Against
this background, it is critical to invest in the discovery of new drugs
that will contribute in the medium to long term control of these
diseases.
A network model for drug discovery against multiple
neglected diseases has been described as a suitable mechanism
to overcome these challenges [1,16]. This approach involves a
coordinated North-South network of collaborators (from both
public and private sectors) which operate low- to medium-
throughput primary screens against target organisms, supported
by medicinal chemistry, drug metabolism and pharmacokinetics
resources to kick-start hit-to-lead and lead optimization
programs. Over the years part of this screening network funded
by TDR has systematically optimized throughput to enable the
testing of hundreds to thousands of pre-selected chemicals in
diverse collections against the following: Plasmodium falciparum,
Leishmania infantum, Trypanosoma brucei, Trypanosoma cruzi, Schisto-
soma mansoni, Onchocerca lienalis or O ochengi (counterparts in cattle
of the human pathogen, Onchocerca volvulus)a n dBrugia malayi.
Higher-throughput methods have been developed for whole
organism antimalarial and anti-Chagas screens, both in industrial
and non-industrial settings [3,4,17–20]. However, the through-
put capacities of whole-organism screens employing the other
pathogens are generally low to medium, permitting parallel
testing of tens or hundreds to a few thousand compounds per
batch [21].
TDR has taken advantage of the availability of multiple assays
available within its network to implement coordinated screening of
highly triaged small-to-medium sized libraries against multiple
organisms, combined with a rapid assessment of mammalian cell
toxicity. Although no in vitro test is fully predictive of in vivo activity,
the TDR strategy is generally accepted as standard practice in
neglected diseases screens [22,23]. Consistent with a virtual
operation, library evaluation, management and sampling are
coordinated with the support of external partners and consultants,
who have extensive experience in medicinal chemistry related to
drug discovery. These consultants help with prioritization of
compound collections to be screened, analysis of the resultant
screening hits thorough chemo-informatics analysis and review of
available literature on the compound or series identified. Data
evaluation, communication and decisions by the drug discovery
network are supported by a readily accessible, centralized database
in which biological and chemical results from distant sites are
uploaded in close to real-time processes for analysis and searching
[24]. The database provides chemoinformatics strategies enabling
substructure searches to analyze and expand structure-activity
relationships (SAR).
Here we present the outcome of screening a set of 10,000
compounds against seven (7) NTD pathogens in whole-organism
assays through a collaborative network model. The implications of
this approach, which we refer to as an integrated multi-pathogen
screening strategy, for enhancing drug discovery productivity and
efficiency for neglected diseases are discussed.
Materials and Methods
Chemical library
A library of 10,000 compounds was purchased from Life
Chemicals (Ukraine) after extensive review and analysis by
medicinal chemists of over 50,000 available diverse structures.
The key criteria used in the selection of molecules to be screened
are diversity and novelty. To ensure a degree of diversity,
selection was enhanced by using the computational informatics
tool [SybylH, Tripos] [25]. Novelty of compounds for the target
diseases was assessed by eliminating previously pursued com-
pounds from in-house screens, available literature and compar-
ison with chemistry already explored for neglected diseases. Based
on this triage, a set of over 12,000 molecules was selected for
further prioritization by analyzing for the presence of toxico-
phores and drug-likeness based on meeting at least 4 criteria in
the Lipinski Rule of fives [26]. The confirmation by Life
Chemical of the availability of close analogs for purchase to
develop SAR, the simplicity of synthetic route and the availability
in amounts .50 mg in the inventory, obviating the need for re-
synthesis to permit testing in animals, was considered as well. The
majority of the 10,000 compounds had a high degree of drug-
likeness, in accordance with the Lipinski Rule of 5 (Figure 1).
Compounds not fully compliant with the Lipinski Rules were
included as a significant number of anti-infective and anti-cancer
drugs do not meet the full criteria [27,28]. Molecules were filtered
to remove duplicate and reactive groups using Accelrys
computational tools [29], to reach the 10,000 unique, non-
reactive compound set. Life Chemicals provided the compounds
with a special plate partitioning system to cover particular
screening and logistics needs for multiple screening of this highly
diverse compound set.
Bioassay, screening logistics and framework
The compound screening logistics and framework, including
sampling, distribution to various screening centers and screening
cascade for the various parasites are shown on Figure 2. Standard
Operating Procedures (SOPs) were implemented according to
established criteria for advancement of compounds from primary
screens to more advanced testing in vitro and for efficacy in animal
models [16]. The integrated panel of antiprotozoal and anthel-
mintic screens used in the present study and the standard
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The search for new drugs for human neglected diseases
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that addressing these infections was necessary for global
poverty reduction. The expansion of discovery and
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the creation of Product Development Partnership (PDP)
enterprises. Despite these efforts, major discovery gaps
remain as, apart from some repurposed drugs and a few
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drug discovery based on coordinated North-South part-
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throughput whole-organism screening assays against
seven NTDs (malaria, leishmaniasis, human African try-
panosomiasis [HAT], Chagas’ disease, schistosomiasis,
onchocerciasis and lymphatic filariasis) together with an
early assessment of compound toxicity in mammalian
cells. We describe a screening campaign of 10,000
molecules, its outcome and the implications of this
strategy for enhancing the efficiency and productivity of
drug discovery for NTDs.
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www.plosntds.org 2 December 2011 | Volume 5 | Issue 12 | e1412Figure 1. LifeChemicals library calculated properties analysis. A: Histograms representing calculated PSA, molecular weight (MW), aLogP and
LogD for the selected Life Chemicals screening set. Overall, the library respects the criteria for the rule of five (maximum acceptable of each criteria
represented by the vertical red line) except the PSA which has a slightly high calculated index. B: This grap is summarizing the Principal Component
Analysis (PCA) of screened library versus PCA of DrugBank library. The DrugBank database is a resource that contains detailed data for about 6800
drugs. Calculated PCA show that the Life Chemical library (represented by the red ellipsis) sits within the 95% PCA confidence index of the DrugBank
library (represented by the blue ellipsis). The PCA calculation was based on the descriptors to account for size, flexibility and polarity of molecules
(molecular weight [size], number of rotatable bonds [flexibility], hydrogen bond acceptors [molecular polarity], hydrogen bond donors [molecular
polarity], topological polar surface area [molecular polarity] and ALogP [molecular polarity].
doi:10.1371/journal.pntd.0001412.g001
Figure 2. Screening logistics and framework. The formatting and distribution of the library to various screening centers on dry ice was handled
by 2 screening partners - Laboratory for Microbiology, Parasitology and Hygiene at the University of Antwerp (LMPH) and the London School of
hygiene and Tropical Medicine (LSHTM). Two shipments were lost (indicated by dark grey boxes) due to logistics problems. Considering the high
variability of screening throughput (P. falciparum=100,000 compounds/month, T. cruzi, T. brucei & L. infantum=10,000 compounds/month, while S.
mansoni (adult worms), B. malayi (adult worms and microfilaria) and O. lienalis/O. ochengi (microfilaria)=1,000 compounds/month), shipments were
handled in 3 batches from increasing size. For batch 2 and 3 and for diseases having 2 different screening sites (Schistosomiasis with London School
of Hygiene and Tropical Medicine (LSHTM) and Theodor Bilharz Institute (TBRI) in Cairo or Onchocerciasis with Northwick Park Institute for Medical
Research (NPIMR) using O. lienalis and the University of Buea (UB) using O. ochengi) it was decided to have molecules individually tested on one single
site.
doi:10.1371/journal.pntd.0001412.g002
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www.plosntds.org 3 December 2011 | Volume 5 | Issue 12 | e1412Table 1. In vitro antiprotozoal [9,16,32–36] and anthelminthic screens [16,30,31,37] screening protocols details.
A. Antiprotozoal screens
For the antiprotozoan screens, stock solutions of each test compound were dissolved in 100% dimethyl sulphoxide (DMSO) at 20 mM and stored at 4uC until used.
Medium throughput screens were performed in 96-well plates containing test compounds at 4-fold dilutions in a dose-titration range (64 mM to 0.25 mM). Each plate
also had blanks, negative controls and reference controls with tests done in duplicate. For all protozoan strains studied, the selectivity index (SI) of each test compound
was calculated from the ratio of the IC50 value determined in normal lung tissue (MRC-5) cells over the IC50 value determined from the dose-response curves (Statview
TM
software package) from each protozoa assayed.
Anti-Plasmodium activity assay Parasites (Plasmodium falciparum K1 strain) were cultured at 37uC under a low oxygen
atmosphere (3% O2,4 %C O 2,a n d9 3 %N 2) in RPMI-1640 supplemented with 10%
human serum and human red blood cells (RBC). Two hundred microliters of infected
RBC suspension (1% parasitemia, 2% hematocrit) were added to each well of the
plates with test compounds and incubated for 72 hours. Parasite multiplication was
measured by the Malstat method wherein 100 microliter of Malstat reagent were
transferred in a new plate and mixed with 20 mL of the hemolysed parasite
suspension for 15 minutes at room temperature. After addition of 20 mL NBT/PES
solution and two hours incubation in the dark, the absorbance was
spectrophotometrically read at 655 nm using a UV microplate reader. Percentage
growth inhibition was calculated compared to the negative blanks. Test compounds
with IC50 of ,0.5 ug/ml and an SI of .100 were considered highly active.
Antitrypanosomal activity assay Trypomastigotes of Trypanosoma brucei brucei Squib-427 strain were cultured at 37uC
and 5% CO2 in Hirumi-9 medium (HMI) and supplemented with 10% FCS. The
antitrypanosomal activity assay was performed by culturing 1.5610
4 trypomastigotes
per well. Cultures were incubated with test compounds for 72 h at 37uC. After
incubation, the growth of the parasites was measured fluorometrically (excitation
wavelength of 530 nm and an emission detection of 590 nm) with the addition of
resazurin to each well and incubated for an additional 24 h. Test compounds with
IC50 of ,0.5 ug/ml and an SI of .100 are considered highly active. Trypanosoma
cruzi, Tulahuen CL2 strain, which are sensitive to treatment with nifurtimox, were
maintained with MRC-5 cells in MEM supplemented with 20 mM L-glutamine,
16.5 mM sodium hydrogen carbonate and 5% FCS at 37uC and 5% CO2. The in vitro
antitrypanosomal activity was studied by culturing 4610
3 MRC-5 cells with 4610
4
Trypanosoma cruzi parasites in each well, and then the wells were treated with each
dilution of Pavetta crassipes extract. The culture plates were incubated for seven days
at 37uC. The presence of parasite growth in each well was assessed by adding b-
galactosidase and chlorophenol red b-D-galactopyranoside to each well and then
incubating the plates for an additional 4 h at 37uC. The color reaction in the presence
of parasites was measured at 540 nm, and the absorbance values were expressed as a
percentage of parasites present in extract treated wells compared to the untreated
controls. Test compounds with IC50 of ,1 ug/ml and an SI of .50 were considered
highly active.
Anti-Leishmania infantum activity assay. Leishmania infantum MHOM/ET/67 amastigotes were collected from an infected
donor hamster and then used to infect primary peritoneal mouse macrophages. Test
compounds were added to 3610
4 Leishmania-infected macrophages (seeded into
each well of a 96-well plate). After 48 h, 5610
4 amastigotes were added to each well
and then incubated for an additional 2 h at 37uC. Treated plates were incubated for
120 h at 37uC and 5% CO2. After the final incubation, each well was treated with
Giemsa stain, and the number of parasites present in each well was counted under a
microscope. The inhibition of parasite growth was expressed as the percentage of
parasites in the compound treated wells versus the parasites in untreated controls.
Test compounds with IC50 of ,0.5 ug/ml and an SI of .20 were considered highly
active.
B. Anthelminthic screens
Anti-Onchocerca (lienalis or ochengi) and
anti-Brugia malayi activity assays
A microfilariae screen was used initially as a higher throughput whole organism
screen to select compounds for later testing against adult worms. Stock solutions of
test compounds were prepared in 100% DMSO diluted into the medium. New
compounds were tested using a 96-well format that contained a confluent feeder
layer of monkey kidney cells. Compounds were tested at 12.5 uM or 10 uM for anti-
Onchocerca (lienalis or ochengi) and anti-Brugia malayi activity assays, respectively.
Culture medium was removed from the feeder layer and the test compound added
followed by a transfer of 5 microfilariae onto each well. Worm viability was assessed
using motility levels during a 5-day observation period. Test compounds with 100%
inhibition of motility were considered highly active.
Anti-Schistosoma activity assay Stock solutions of 5 mg/ml of test compounds were prepared in 100% DMSO
immediately before use. Test compounds were added to each culture well containing
Schistosoma mansoni adult worms (5 each for male and female worms) in complete
DMEM media) at a final concentration of 10 ug/ml or 12.5 mM. Worms were examined
microscopically using an inverted microscope at intervals of 24, 48 and 120 h. Test
compounds with 100% inhibition of motility were considered highly active.
doi:10.1371/journal.pntd.0001412.t001
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[9,16,30–35] (see Table 1).
Appropriate reference drugs, obtained either from Sigma or
WHO-TDR collection, were used as positive controls [9,16,30–
35]: chloroquine sulphate for P. falciparum, amphotericin B for L.
infantum, nifurtimox for T cruzi, suramin and pentamidine for T.
brucei, praziquantel for S. mansoni, immiticide, amocarzine and
ivermectin for O. lienalis or O. ochengi, and ivermectin and
diethylcarbamazine for B. malayi.
The compound set was tested against the following parasites:
intra-erythrocytic forms in human red blood cells of P. falciparum
K1 strain (malaria) [9,16,32,33,35], bloodstream forms of T. brucei
Squib 427 strain (human African trypanosomiasis, HAT)
[16,31,32,34], intracellular amastigotes of T. cruzi Tulahuen
CL2, beta- galactosidase strain (Chagas’ Disease) [16,32–35],
intracellular amastigotes of L. infantum MHOM/MA(BE)/67
(leishmaniasis) [16,32–36], larval and/or adult worms of S. mansoni
Puerto Rican strain (schistosomiasis) [16,31,37], microfilariae of B.
malayi (lymphatic filariasis) [16,30] and microfilariae of O. ochengi or
O. lienalis (onchocerciasis) [16,30]. It should be noted that the
human pathogen for onchocerciasis is Onchocerca volvulus, but due to
lack of a suitable in vitro assay or animal models for this pathogen,
O. ochengi and lienalis, which are both animal pathogens, are used in
the primary and secondary assays [16,30].
In some cases, particularly for the antifilarial screens, a second
whole organism test with adult stage parasites is included prior to
animal evaluation. The decision to utilize microfilariae for primary
screening was based on throughput and biological considerations.
It is difficult to acquire enough adult filariae to enable screening
more than 1000 compounds per year [21], a rate far lower than
needed for timely evaluation of the available compounds. In light
of this situation, and considering that we are targeting molecules
that are active on both stages, microfilariae screening was adopted
as a suitable filter to identify compounds with potential macro-
filaricidal activity [30].
An important part of the screen is the evaluation of all
compounds for cytotoxicity using the diploid human embryonic
lung fibroblast MRC-5 cell line (Figure 2). Further evaluation of
cytotoxicity also takes advantage of the assays for intracellular
protozoan parasites, as in the case of L. infantum and T. cruzi, which
include murine peritoneal macrophage host cells [36] and MRC-
5SV2 human lung fibroblast cells, respectively, in the culture
system.
Analysis of screening results
Hits identified from the screens were initially compared with
cytotoxicity data for selectivity. Further filtering of the data was
done using the published ‘Hit’ criteria for all pathogens combined
with classical medicinal chemistry criteria [16]. All screening
actives were evaluated for prior art through searches of Chemical
Abstracts, and any relationship to compounds in development in
related or other therapeutic areas investigated by substructure
searches in drugs databases, principally the Investigational Drugs
database (IDdb3; now Thomson Reuters Partnering). Substructure
searches were also done in the TDR database covering previously
tested libraries and medicinal chemistry projects.
Results
Screening results from seven pathogens
From the screen of 10,000 compounds, 744 were identified as
active against at least one pathogen (Figure 3). Cytotoxicity data
were used to aid selection and prioritization of compounds for
progression to the next stage of the lead discovery process. To the
best of our knowledge, this is the first time in which comparative
data from essentially simultaneous screens against multiple
neglected diseases pathogens and cytotoxicity data have been
used in an integrated analysis for lead identification. Specific hit
series from each pathogen are described below. To further
illustrate the results from this multi-pathogen and cytotoxicity
screening, a series of case examples with chemical structures
covering one or more diseases are presented (Table S1). Identified
hits are either referred to as series, consisting of a group of active
molecules having similar core chemical structures/scaffolds, or as
singletons if only one member of a chemical family is identified as
active against a pathogen.
P. falciparum (Malaria). 33 of the 744 active compounds
met the potency criteria of IC50,0.5 mg/ml for P. falciparum [16].
Further evaluation of these molecules resulted in the prioritization
of 7 compounds, encompassed in 2 series and 2 singletons. One
series, comprised of 2 molecules (not shown), is structurally related
to a previously identified chemical series which is being optimized
by an external partner (Merck Serono), providing an important
validation of the library and the concept. The remaining series
[structure # 8] with IC50 values of ,0.15 mg/ml is structurally
related to, but nonetheless distinct from, a series with activity
against T. cruzi and T. brucei in vitro [structure # 9, 10, 11]. One
singleton [structure # 15] is structurally related to a series with
activity against L. infantum [structure # 38] and the other was
distinguished by a notable lack of activity with close analogs tested
in this assay and therefore is of interest [structure # 16].
T. brucei (HAT). 108 of the 744 actives passed the initial
criterion of IC50,0.5 mg/ml for bloodstream forms of T. brucei
Squib 427 strain. Of these, 67 compounds exemplified in
[structures #1 to 6] were removed from further consideration
due to poor selectivity vis-a `-vis mammalian cells. An additional 7
compounds were discarded based on undesirable chemical
attributes [structure # 39]. Of the remaining 31 molecules,
TDR84116 [structure #37; proposed for evaluation at Merck
Serono], showed exceptional potency (IC50=0.08 mg/ml) against
T. brucei and was later reconfirmed with a similar potency
(0.02 mg/ml, SI.100) against T. brucei rhodesiense (STIB-900). The
remaining 20 actives represent 6 structural series and 11
singletons. All were less potent than TDR84116, with many
showing IC50 values near the cut-off point. Some of these series are
also active against T. cruzi [structure #7 and Figure 4).
One series and two singletons were prioritized for further
investigations [structures #17, 18 and #19, 20, respectively]. One
series was prioritized for the onchocerciasis program (data not
shown), while a third series appears interesting for a joint HAT/
Chagas project [see structures # 11, 12 and Figure 4].
T. cruzi (Chagas’ Disease). 171 of the 744 actives passed
the initial criterion of IC50,1 mg/ml for T. cruzi Tulahuen CL2,
beta galactosidase strain maintained on MRC-5SV2 cells in MEM
medium (MRC-5 cell/parasite inoculum: 4.10
3 cells/well+4.10
4
parasites/well), supplemented with 200 mM L-glutamine,
16.5 mM NaHCO3 and 5% heat inactivated fetal calf serum.
Not sure that the details of the culture system and medium belong
here. Of these, 109 were eliminated [structures #1–6] for poor
selectivity versus mammalian cells (SI,50) and an additional 11
due to undesirable chemical attributes. The remaining 51
compounds were sorted into 10 series (45 compounds) and 6
singletons [structures # 21, 22]. Two of these series with excellent
potency against T. cruzi, limited activity against other protozoa and
SI values .50 (not shown), have been transferred to DNDi for
further evaluation.
A series of 2-aminothiazole derivatives [structure # 23] was
transferred to the University of Sao Paolo for further exploration,
Parallel Screening on Neglected Diseases Pathogens
www.plosntds.org 5 December 2011 | Volume 5 | Issue 12 | e1412Figure 3. Comparison of the 744 hits from different pathogens and cytotoxicity. The 744 hits identified on the various pathogens are
sorted by compound identifier (ID). Each colored line represents an active molecule and each column represents an assay for a pathogen or
cytotoxicity (C=cytotoxicity, M=malaria, H=HAT, CD=Chagas disease, L=Leishmaniasis, S=Schistosomiasis, LF=Lymphatic Filariasis (microfilaria)
and O=Onchocerciasis (microfilaria). Except for cytotoxicity, where active molecules are highlighted in red (activity,1 mg/ml), orange (1 mg/
ml,activity,2 mg/ml) or gold ((2 mg/ml,activity,5 mg/ml) depending on the degree of activity, all molecules meeting the activity criteria for a
disease pathogen (see Results) are highlighted in green and molecules having some borderline activity (Malaria and HAT: 0.5 mg/ml,activity,2 mg/
ml, Chagas Disease: 1 mg/ml,activity,4 mg/ml, Leishmaniasis: 2 mg/ml,activity,4 mg/ml and Schistosomiasis/Onchocerciasis/Lymphatic Filariasis:
.75% motility reduction at 12.5 mM) are highlighted in yellow. Grey box represent missing results. Further details on color coding are available
below.
doi:10.1371/journal.pntd.0001412.g003
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the series transferred to DNDi. A series with a benzo(thiazol-2-
yl)acetamide pharmacophore [structure # 9, 10, 24] included 14
molecules with activity at concentrations as low as 0.22 mg/ml
with an interesting pattern of selectivity against other pathogens.
However, some showed limited selectivity against mammalian
cells. Additional investment of medicinal chemistry should be
made to clarify the potential for selectivity among the various
parasites and especially with regard to mammalian cells, prior to
analysis in vivo.
L. infantum (leishmaniasis). 115 compounds met the
criterion of IC50,2 mg/ml against L. infantum amastigotes in
macrophages. Of these, 30 [structure # 25] were discarded for
poor selectivity against mammalian cells (SI,20) and another 8
for undesirable chemical attributes [structures # 1, 2, 5, 26]. The
remaining 77 compounds were organized in 11 series (58
compounds) and 22 singletons. In addition to the series
described above for P. falciparum [structure # 16], several series
are considered high priority based on potency (IC50,0.5 mg/ml in
$2 compounds) and SI values .30, as well as on preliminary SAR
and chemical considerations. One series [structure # 36, 40, 41],
includes 17 molecules with no previous evidence of antiparasitic
applications and, for most of the molecules, a clean selectivity
profile against tested pathogens. Two other high interest series
with respectively 9 and 6 analogues are represented by structures
#42 and #43.
S. mansoni (schistosomiasis). A subset of 9478 of the
10,000 compound collection was tested against the Puerto Rican
strain of S. mansoni. 6144 of these were tested in a primary larval
assay [37] followed by the ex-vivo adult secondary screen. The
remainder was screened only in the adult assay. 65 of the 744
actives from all pathogens met the minimum criteria for activity
against adult S. mansoni: (i.e., 100% reduction in worm motility at a
concentration of 10 mg/ml or 12.5 mM). The 65 compounds were
sorted by chemical attractiveness, potency against adult
schistosomes in culture, selectivity against other parasites, and
toxicity to mammalian cells in culture. Based on this analysis, 5
series encompassing 13 compounds were chosen for advancement
through the African Network for Drug and Diagnostic Innovation
(ANDI) [11] and other PDPs. Representative structures [structures
# 13, 27, 28] are shown (Table S1). These compounds are
unburdened by obvious toxic moieties, have acceptable
compliance with the Lipinski rules, are selectively active against
schistosomes and are not overtly toxic to mammalian cells. It has
unfortunately not been possible to titrate all of these hits in culture;
of about 50% for which such data are available, none has an
IC50,2 mg/ml (which is the initial potency criteria). Further
analysis of these series, including confirmation, titration, testing of
additional analogs and assays of in vivo activity in mouse models of
schistosomiasis, is needed to prove that any has sufficient merit to
warrant further development.
Brugia malayi (lymphatic filariasis). As result of logistics
issues attributed to lost shipments of some compounds, only 6160
molecules of the 10,000 compound set were tested, at a uniform
molarity [30], against B. malayi, including 6063 against
microfilariae and 756 against adult worms (these sets overlap).
Activity criteria were 100% loss of motility at 10 mM for either
stage. Greatest priority was given to compounds with activity
against adult worms, as no macrofilaricide is available for use in
control campaigns and the activity of ivermectin as a
microfilaricidal agent is unlikely to be bettered in a new series.
Of the test set, 53 compounds met the activity criterion for
microfilariae (100% motility reduction) and an additional 58
inhibited adult worm motility $75% at 10 mM. These were
titrated to determine an IC50 value to support prioritization.
Following cytotoxicity triage [structures # 1, 4, 6], eight
Figure 4. Comparison of Chagas (T. cruzi) and HAT (T. brucei) hits that are non cytotoxic. Graph show IC50 values of all non cytotoxic
compounds (IC50.5 ug/ml on MRC5 cells) on Chagas (X axes) and on HAT (Y axes). Interesting series are grouped into 3 sub groups as follows: 1) the
compounds that are active against only T. cruzi are represented by large light blue squares around the Y axes, 2) the compounds active against only T.
brucei are represented by small dark blue squares around the X axes, and 3) compounds active against both pathogens identified as large dark blue
close to the cross axes. The compounds in group 3 are potential candidates for joint development for the 2 diseases.
doi:10.1371/journal.pntd.0001412.g004
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100% inhibition of adult worm motility), four of which were also
active against microfilariae [structures # 14, 29, 30, 32]. An
additional 10 compounds with inhibition of motility $75% at
10 mM and an experimentally determined IC50 value were also
considered. Of these, the most interesting was TDR76699
[structure # 29]; this compound has very good activity against
adult worms (IC50=0.1 mg/ml) and is also active against
microfilariae (IC50=0.7 mg/ml). None of the other compounds
tested against adult parasites had IC50 values #0.5 mg/ml, a
threshold which would reduce concerns about specificity.
However, a few series [structures # 31, 33, 34], appear
interesting for future medicinal chemistry projects.
O. ochengi or O. lienalis (onchocerciasis). 4240 compound
s were screened against O. ochengi at the University of Buea in
Cameroon, while a subset of 5088 compounds was successfully
screened in UK by the Northwick Park Institute for Medical
Research against O. lienalis, at a uniform molarity [30]. 7
compounds showed activity against microfilariae of O. lienalis and
330 were active against microfilaria of O. ochengi (100% inhibition of
motility at 12.5 mM). After removing molecules that were toxic to
mammalian cells (IC50,5 mg/ml), 292 molecules remained for
further evaluation. It is interesting to note that of the 330 O. ochengi
microfilariapositives, 48havealreadybeen foundto alsohavefullto
moderate activity on the adult worms. From the latter sub-set, 3
distinct chemical series and one singleton [structure # 35] were
active against both microfilaria and adults. One series [structures #
2, 3] was deemed not interesting due to lack of selectivity against
mammalian cells. The remaining series is being transferred to
ANDI for further progression as part of a new collaboration.
In summary, of the hits that survived toxicity triage, at least four
series covering malaria, schistosomiasis, Chagas’ disease and
human African trypanosomiasis have been transferred to external
partners (Merck Serono, DNDi and the University of Sao Paolo)
for further exploration of SAR, whilst promising series for
leishmaniasis, schistosomiasis and onchocerciasis are being
transferred to ANDI. Details, including structures of hits for
malaria, HAT, Chagas’ Disease and LF, that are not restricted by
any legal agreements, are available through the TDR target
database - www.tdrtargets.org [38,39].
Discussion
Historically, antiparasitic drug discovery has relied on whole
organism screens, as exemplified by recent reports of promising
leads from whole-malaria parasite screens [4,13,18]. Although
progress has been made in drug discovery built on mechanism-
based screening approaches and in identifying parasite proteins
which are good drug targets, clear success stories are not yet
available [38,39]. Similar but much more limited screening efforts
have been devoted to less publicized NTDs, including those caused
by kinetoplastids and helminths. Whole parasite screening for drug
lead identification for kinetoplastids has been limited, and outside of
the animal health industry,few systematiceffortshavebeendirected
at screening against helminths. TDR efforts to identify novel
starting points using whole-organism screening for the more
neglected diseases warrant recognition and further support.
This work underscores the need for increased efforts in
integrated screens for neglected diseases. The use of specific
library selection methods which exclude previously described or
known scaffolds and the early filtering of active molecules provides
novel mechanisms to enhance screening outcomes for NTDs. A
striking outcome of the current approach is the low number of
actives identified for P. falciparum. This is due to the nature of the
compound set and the fact that most known actives against P.
falciparum were eliminated from the library. However, one of the
identified novel malaria hit series is structurally similar to a
previously identified series undergoing lead optimization in
collaboration with Merck Serono (data not shown). This screening
strategy also highlights the critical importance and value of early
cytotoxicity assessment (Figure 3 and Table S1). This single test
allowed us to rapidly discriminate highly attractive series from
poorly selective molecules, as most cytotoxic compounds also hit
multiple pathogens. It therefore helps to remove nearly all non-
selective molecules, meaning molecules active against .2
unrelated pathogens [structures # 1 to 6]. It is noteworthy that
we identified only one molecule [structure # 36], with a
cytotoxicity IC50,5 mg/ml that was active against .2 pathogens.
The cost of resolving selectivity issues in secondary assays, or
even later during clinical trials, can detract greatly from efficiency
of the overall operation. We consider that lead series identified in
in vitro assays, subjected to cross pathogen analysis as described in
this paper, represent the most promising candidates for in vivo
follow-up, minimizing resource wastage on unpromising hits.
Although discovery is an expensive endeavor, expansion of
chemistry or transition of a compound to development with
associated ‘hit-to-lead’, lead optimization and preclinical toxico-
logical assessment markedly escalates the investment. It is vital to
advance only compounds that have a legitimate chance of success,
especially with limited resources. Our approach of screening
against multiple pathogens represents a path to overcoming some
of the challenges of early drug discovery.
Our results also show that none of the anthelmintic hit series
which showed no appreciable cytotoxicity was active on . one
helminth pathogen, i.e., identified positives are selectively active in
the schistosomiasis, onchocerciasis or LF screens [Table S1,
structure # 27–35]. This again justifies the multiple species
approach, as it helps to rapidly identify compounds that are active
against multiple pathogens. Therefore, it helps to determine
whether such overlapping activity is indicative of general toxicity
as well as different or related mechanisms of action in different or
related species, respectively. As indicated earlier, some hits against
T. cruzi also showed activity against T. brucei [structure #11, 12 and
Figure 4]. The activity shown against related kinetoplastid parasites
(T. brucei and T cruzi) is suggestive of a specific mechanism of action.
Although azoles may be active against different parasites, they
probably act by different mechanisms in each [40]. The cross-
Phylum activity of artemisinins is another example [41], but
depending on the target product profile for the disease [1,42], this
kind of activity should be a signal for caution in pursuing a series. It
should also be notedthat a few non-cytotoxic hitsagainst one or two
protozoaarealsoactiveagainst onehelminth(Table S1,structure #
30). Noteworthy are series in which some compounds display an
activity against one species, whereas other compounds display
activity against another species. The mechanism of action may be
the same, but with a slight difference of target structure between the
2 parasites. In this case, the chemical exploration of SAR could be
beneficial to research on both species.
The major benefit of the current approach centers on the
synergy gained by simultaneously screening a compound collec-
tion against multiple organisms. Salient advantages include:
i) Compound handling can be better coordinated and
organized to gain efficiency in the distribution process.
ii) Interpretation and analysis of data can be done in a
coordinated manner, so that decisions about compound
progression can be integrated with programmatic priorities
for the various indications.
Parallel Screening on Neglected Diseases Pathogens
www.plosntds.org 8 December 2011 | Volume 5 | Issue 12 | e1412iii) Areas of greatest need can be balanced with quality of hits
(in both chemical and biological terms) to produce a
portfolio of leads that offers the best chance for making
significant advances in their respective area.
iv) It provides early validation of and confidence in hits
identified and prioritized for the various pathogens.
v) It helps to rapidly share lessons and create value around a
set of compounds due to the significant amount of data
collected from the multiple screens.
It should be emphasized that it has been traditionally difficult to
generate novel, robust hits against leishmaniasis, leaving the
current screening and drug discovery pipeline weak for this disease
(www.dndi.org). It is therefore remarkable to see the interesting hit
rate found in our screening campaign. The fact that we discovered
different compound series, containing up to 17 similar molecules
active against L. infantum, gives some degree of confidence to the
results. This again points to the usefulness of careful selection of
chemical libraries used for screening.
Presently, whole-organism screens for many of these parasites
are not amenable to the scale of throughput possible with P.
falciparum in erythrocytes [20]. However, the integrated screens
against the 7 pathogens reported here demonstrate the feasibility
and importance of leveraging resources across parasite screens. It
can also aid the development of SAR data around identified
starting points. In the context of the actives described here,
expansion of a series should be accomplished by acquisition of
close-in analogs such that hit series from the various screens can be
further prioritized across indications. It would be interesting to
evaluate the previously identified molecules from the various
antimalarial screening projects using the approach described in
this paper. This early evaluation could help to select the most
promising series for development based on selectivity, thereby
limiting the high risk inherent in transitioning molecules from
early discovery to early development.
While the integrated screens presented here represent current
‘‘best practice’’, many unknowns plague the screening pathways
for new antiparasitic agents for human use. The dearth of safe and
effective drugs for most NTDs means that it is difficult to fully
validate the screening streams. Some of the most important
antiparasitic drugs seem to require an interaction with the host
immune system, for example, praziquantel for schistosomiasis and
ivermectin for filariasis [2], a paradigm that is difficult to
incorporate into a whole-organism screen in culture. We do not
know how closely parasites in culture resemble parasites in a host
in terms of drug target expression and the role of these targets in
survival in the host. Some of the screens employ representative
species for discovery, even though there are well known differences
in sensitivity of other species in the same genus or clade
(oxamniquine, for example, is active against S. mansoni but inactive
against S. haematobium [42]. In some cases, the target parasite
species of greatest interest is unavailable for screening (for example
Plasmodium vivax, Wuchereria bancrofti, Onchocerca volvulus). Finally, the
screens do not always employ the most important target stage of
the parasite (microfilariae vs. adult filariae, for example). The
screens are thus compromises between ideal and practical
operations, with the central assumption inherent in this strategy:
that drugs with broad-spectrum activity within a parasite group
will be discovered and are of the greatest interest. On the logistics
side: the network screening model requires careful plate formatting
and repartitioning to minimize risks of inability to trace inter or
intra screening variations.
Conclusion and future perspectives
The integrated, multi-pathogen, collaborative approach to the
discovery of new chemical entities described here promises to
increase efficiency while reducing costs and second-stage attrition
in the discovery of high-quality leads compared to operations
which target pathogens individually. Although this work focuses on
the initial whole organism pathogen screening programme for hit
identification, it should be stressed that it is part of an integrated
North-South drug discovery platform that includes medicinal
chemistry, pharmacokinetics and early toxicology [1,16]. The
approach needs to be scaled up and implemented more broadly,
especially in developing countries, to ensure that the diverse set of
NTDs receives the attention they warrant. This will require
enhanced financial support and commitment from stakeholders as
the current funding level is grossly insufficient relative to the
burden of these infections on the developing world. In this context,
a concerted global effort that interfaces with and strengthens the
R&D capacity of institutions in developing countries, for example
through ANDI, would greatly maximize resources and ensure that
resultant drug leads are efficiently advanced. In support of this
approach, some of the hits described in this paper are being
transferred to ANDI to support innovation and capacity building
in Africa. In addition, the chemical structures for most of the hits
from the different pathogens described in this paper can be
accessed through the TDR targets database (www.tdrtargets.org),
a global open source database of molecular targets and drug like
compounds that supports open innovation for infectious tropical
diseases [38,39].
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